- Investing Ideas
- /
- Swiss Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Swiss Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Results
2
0 new
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
2 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
GALD | CHF 100.64 | 2.3% | n/a | CHF 23.9b | CHF 99.88 | PS6.1x | E44.6% | n/a | ||
SKAN | CHF 76.20 | -0.3% | -5.7% | CHF 1.7b | CHF 90.67 | PE53.1x | E18.7% | 0.5% |
Page 1 of 1